Dyania Health, a technology company founded in 2020, has raised $10 million in a Series A funding round led by HealthX Ventures, with participation from Tech Square Ventures and Cleveland Clinic Ventures.
The company aims to revolutionize patient chart review through the use of artificial intelligence. Their proprietary platform, Synapsis AI, leverages advanced large language model (LLM) technology to automate the review and abstraction of medical records, improving the efficiency of clinical trial pre-screening and observational studies.
The funding will be used to expand Dyania's AI capabilities and establish partnerships with healthcare organizations to enhance clinical research outcomes and patient care. Dyania Health previously secured $5.3 million in seed funding in 2022, indicating significant growth and innovation. The company plans to scale its engineering team to meet the increasing demand for their technology.
Dyania Health's Synapsis AI platform is currently deployed in large healthcare systems, facilitating enterprise-wide clinical trial pre-screening and automating complex registry reporting. The technology reduces the manual workload for healthcare professionals, allowing for more accurate and timely patient care.
The AI can process information that would typically take a human between 90 minutes to two hours in just half a second. The platform excels in handling unstructured medical data, which constitutes approximately 80% of electronic medical records (EMRs). This unstructured data includes physician notes, pathology reports, and imaging notes, making it challenging for clinicians to quickly identify patients eligible for clinical trials.
Dyania Health's technology can analyze 1,000 EMRs in just 8.3 minutes, significantly faster than a medical professional. This capability streamlines patient identification and improves the quality of care.
Dyania Health adopted a collaborative approach to AI development, combining the expertise of full-time physicians with applied AI researchers. The multidisciplinary team focused on building large language models tailored for medical applications to meet the demands of clinical research.
The company's journey began during the COVID-19 pandemic, which allowed them to annotate extensive datasets and train their LLM effectively. By acquiring GPU resources early on, Dyania Health positioned itself for continuous innovation and model training, consistently outperforming human experts in medical chart review.
Dyania Health has established strategic partnerships with healthcare systems and life sciences companies, particularly academic medical centers with computational infrastructure and clinical research operations. The collaboration with Cleveland Clinic has been successful, leading to plans for an enterprise-wide rollout of Synapsis AI in cancer and cardiovascular disease areas.
The integration of Dyania Health's technology is expected to streamline the clinical trial recruitment process, making it easier for patients to access trials and advancing scientific progress. The AI's ability to screen EMRs for eligibility criteria represents a significant advancement in reducing bottlenecks in clinical research.
As Dyania Health continues to innovate and expand, the implications for the healthcare industry are significant. Automating and enhancing the review of medical records improves operational efficiency and can potentially save lives by ensuring timely access to clinical trials and therapies.
The ongoing development of AI technologies in healthcare is reshaping the landscape, leading to better outcomes for patients and providers.